OXYNTOMODULIN ANALOGS

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) ago...

Full description

Saved in:
Bibliographic Details
Main Authors MARSH DONALD J, DIMARCHI RICHARD, SINHA ROY RANABIR, CAPITO ELENA, BIANCHI ELISABETTA, INGALLINELLA PAOLO, PESSI ANTONELLO, CARRINGTON PAUL E, POCAI ALESSANDRO, SANTOPRETE ALESSIA, EIERMANN GEORGE J, METZGER JOSEPH M, WARD BRIAN
Format Patent
LanguageEnglish
Korean
Published 27.06.2012
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
STEROIDS
Online AccessGet full text

Cover

More Information
Summary:Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
Bibliography:Application Number: KR20117021805